The UK based not-for-profit LifeArc is excited to announce the launch of an international funding call in February as part of its drug repurposing programme in Motor Neuron Disease (MND). This £5 million funding initiative aims to expedite the development of more effective repurposed treatments for a wider spectrum of MND patients.
LifeArc is actively seeking expressions of interest from research teams in academia and small and medium-sized enterprises (SMEs) possessing a repurposed drug and therapeutic target, accompanied by preliminary experimental evidence showcasing its potential in treating MND. Successful applicants will be required to develop project plans designed to deliver robust preclinical data-packages facilitating drug prioritisation for future clinical studies.
Key Information:
- All applicants are encouraged to read and follow the Guiding principles for drug discovery and development.
- Funding of up to £750,000 will be made available for successful applicants
- All applicants will benefit from early access to LifeArc expertise in translational research and drug-repurposing.
For additional details please visit LifeArc’s dedicated Neurodegeneration pages and for any informal enquiries, feel free to reach out by email to mnd@lifearc.org
Visit funding web page
(https://www.lifearc.org/strategy/neurodegeneration/)
